中国临床药理学杂志2017，Vol.33Issue(3)：195-198,4.DOI:10.13699/j.cnki.1001-6821.2017.03.001
阿托伐他汀钙片治疗脑卒中并脑微出血的临床研究
Clinical trial of atorvastatin calcium tablets in the treatment of stroke with cerebral microbleeds
摘要
Abstract
Objective To observe the clinical efficacy and safety of atorvastatin calcium combined with amlodipine besylate and metoprolol in the treatment of stroke with cerebral microbleeds.Methods Eighty stroke patients with cerebral microbleeds were randomized into control group (n =40 cases) and treatment group (n =40 cases).Control group was given oral amlodipine besylate 5 mg qd and metoprolol succinate sustained-release tablets 47.5 mg qd after getting up in the morning.Treatment group was treated with atorvastatin calcium 20 mg qd before going to bed,on the basis of control group.Two groups were treated for 6 months.The clinical efficacy,number of cerebral microbleeds,total cholesterol(TC),low density lipid protein-cholesterin (LDL-C),nitric oxide (NO),brachial artery flow-mediated dilatation (FMD),brachial-ankle arterial pulse wave velocity (baPMV),systolic blood pressure(SBP),diastolic blood pressure (DBP) and the adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 87.50％ (35/40 cases) and 67.50％ (27/40 cases),with significant difference(P ＜0.05).Before treatment and after treatment 2 weeks and 6 months,the number of cerebral microbleeds in treatment group were (4.14 ± 0.96),(2.82 ± 0.73) and (1.70 ± 0.51) respectively,while in control group was (4.14 ± 1.01),(2.97 ± 0.75) and (2.41 ± 0.66) respectively,the differences within group before and after treatment and between groups were significant(P ＜ 0.05).There was significant difference between groups at 6 months after treatment(P ＜ 0.05).After treatment 6 months,the main indexes in treatment and control groups were compared:TC were (1.98 ± 0.98),(2.71 ± 0.43) mmol · L-1;LDL-C were (0.87±0.15),(1.50±0.24)mmol · L-1;baPMV were(1418.18 ±40.26),(1519.47 ±51.66) cm · s-1;SBP were (112.26 ± 18.01),(122.34 ± 19.58) mmHg;DBP were (66.11 ± 10.64),(73.70 ± 11.80) mmHg;NO were (79.99 ± 12.84),(70.19 ± 11.25) μmol · L-1;FMD were (9.99 ± 1.60) ％,(9.00 ± 1.44) ％,with statistically significant difference(P ＜ 0.05).In the treatment and control groups,the incidence of cerebral hemorrhage were 2.50％ and 7.50％;thrombosis were 0 and 5.00％;cerebral infarction were 2.50％ and 10.00％;liver and kidney function injury were 2.50％ and 0,without significant difference (P ＞ O.05).Conclusion Atorvastatin calcium combined with amlodipine besylate and metoprolol has a definitive clinical efficacy in the treatment of stroke with cerebral microbleeds,which can decrease blood pressure,regulate vascular endothelial function,reduce the number of cerebral mierobleeds,without increasing the incidence of cerebrovascular adverse events.关键词
阿托伐他汀钙/苯磺酸氯氨地平/美托洛尔/脑卒中/脑微出血/安全性Key words
atorvastatin calcium/amlodipine besylate/metoprolol/stroke/cerebral microbleeds/safety分类
医药卫生引用本文复制引用
尚进,杨杰..阿托伐他汀钙片治疗脑卒中并脑微出血的临床研究[J].中国临床药理学杂志,2017,33(3):195-198,4.基金项目
国家自然科学基金资助项目(81471199) （81471199）
